1. Search Result
Search Result
Results for "

CT

" in MedChemExpress (MCE) Product Catalog:

117

Inhibitors & Agonists

1

Fluorescent Dye

2

Biochemical Assay Reagents

13

Peptides

12

Inhibitory Antibodies

3

Natural
Products

47

Recombinant Proteins

38

Antibodies

1

Click Chemistry

6

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-16433

    CT 112

    Aldose Reductase Metabolic Disease Inflammation/Immunology
    Risarestat (CT-112), an aldose reductase inhibitor, is developed for the treatment of diabetic complications.
    Risarestat
  • HY-148514

    PDGFR Cancer
    CT52923 is a selective, orally active platelet-derived growth factor receptor (PDGFR) antagonist. CT52923 also is an ATP-competitive inhibitor. CT52923 can be used for the research variety of pathological diseases, including atherosclerosis, glomerulonephritis, liver cirrhosis, pulmonary fibrosis, and cancer .
    CT52923
  • HY-153996

    Deubiquitinase Cancer
    CT1113 is a potent USP28 and USP25 inhibitor. CT1113 decreases the MYC level in vivo,exhibits anti-tumor activity in mouse pancreatic cancer CDX model .
    CT1113
  • HY-118982

    Reactive Oxygen Species (ROS) Cancer
    CT-2584 is a chemotherapeutic compound that reduces the expression of NKEF-B in several tumor cell types and kills tumor cells by inducing the production of ROS in mitochondria, commonly used in cancer research .
    CT-2584
  • HY-109084

    CT-707

    FAK Cancer
    Conteltinib (CT-707) is a multi-kinase inhibitor targeting FAK, ALK, and Pyk2. Conteltinib exerts significant inhibitory effect on FAK with an IC50 of 1.6 nM .
    Conteltinib
  • HY-168894

    Ferroptosis Cancer
    CT-1 is a derivative of Cryptotanshinone (HY-N0174). CT-1 is a ferroptosis inducer. CT-1 promotes the interaction between NCOA4 and ferritin by targeting FTH1, triggering ferritinophagy-mediated ferroptosis. CT-1 has anticancer activity against triple-negative breast cancer (TNBC). CT-1 induces ferroptosis in both N2-type tumor-associated neutrophils (TANs) and TNBC cancer cells .
    CT-1
  • HY-150596

    Apoptosis Bcl-2 Family JNK Cancer
    CT1-3 is a potent anticancer agent. CT1-3 induces mitochondria-mediated apoptosis by regulating JNK/Bcl-2/Bax/XIAP pathway. CT1-3 suppresses the epithelial mesenchymal transition (EMT) potential of human cancer cells (HCCs) via regulating the E-cadherin/Snail axis, thus inhibits tumorigenesis. CT1-3 has a strong antitumor effect in mice model and exhibits no significant hepatic and renal toxicity .
    CT1-3
  • HY-10182C

    CHIR-99021 dihydrochloride; CT99021 dihydrochloride

    GSK-3 β-catenin Wnt Metabolic Disease Cancer
    Laduviglusib;CHIR 99021;CHIR99021;CHIR-99021;CT99021;CT 99021;CT-99021
    Laduviglusib dihydrochloride
  • HY-108704

    Bcr-Abl Cancer
    CT-721 is a potent and time-dependent Bcr-Abl kinase inhibitor with an IC50 of 21.3 nM for wild-type Bcr-Abl kinase, and possesses anti-chronic myeloid leukemia (CML) activities . CT-721 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    CT-721
  • HY-P10993

    Bcl-2 Family Cancer
    CT20p is an anticancer peptide based on the C hydrophobic terminus of Bax. CT20p has a unique cytotoxic effect independent of full-length Bax, and can act on mitochondria, leading to fusion-like aggregation and mitochondrial membrane hyperpolarization. CT20p can reduce α5β1 integrin levels and inhibit F-actin polymerization, thereby destroying the cytoskeleton and preventing cell attachment. CT20p can be used in the study of breast cancer .
    CT20p
  • HY-P990077

    CT-011; MDV9300

    PD-1/PD-L1 Cancer
    Pidilizumab (CT-011) is a humanized IgG1k anti-PD-1 monoclonal antibody. Pidilizumab acts as a DLL1 antagonist. Pidilizumab has the potential for hematologic malignancies research .
    Pidilizumab
  • HY-70073
    Zaurategrast
    3 Publications Verification

    CT7758

    Integrin Inflammation/Immunology
    Zaurategrast (CT7758) is a potent and oral-effective α4-integrin inhibitor .
    Zaurategrast
  • HY-P99620

    CT-P22; CT120

    Influenza Virus Infection
    Firivumab (CT-P22; CT120) is a human IgG1 monoclonal influenza A virus hemagglutinin (Anti-IAV HA) antibody. Firivumab is capable of neutralizing H1N1, H5N1, H6N1, H6N2, H8N4, H8N8, H9N2 and H12N7. Firivumab shows protection against H1N1 virus in mice .
    Firivumab
  • HY-109084A

    CT-707 tetrahydrochloride

    FAK Cancer
    Conteltinib tetrahydrochloride (CT-707 tetrahydrochloride) is the tetrahydrochloride salt form of Conteltinib (HY-109084). Conteltinib tetrahydrochloride is the inhibitor for FAK (IC50=1.6 nM), ALK, and Pyk2. Conteltinib tetrahydrochloride exhibits a synergistic anti-tumor efficacy with Cabozantinib (HY-13016) .
    Conteltinib tetrahydrochloride
  • HY-RS03279

    Small Interfering RNA (siRNA) Others

    CT83 Human Pre-designed siRNA Set A contains three designed siRNAs for CT83 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    CT83 Human Pre-designed siRNA Set A
    CT83 Human Pre-designed siRNA Set A
  • HY-RS03278

    Small Interfering RNA (siRNA) Others

    CT55 Human Pre-designed siRNA Set A contains three designed siRNAs for CT55 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    CT55 Human Pre-designed siRNA Set A
    CT55 Human Pre-designed siRNA Set A
  • HY-P991340

    PAI-1 Cardiovascular Disease
    CT140 is a human IgG4 monoclonal antibody (mAb) targeting PAI-1. Recommend Isotype Controls: Human IgG4 kappa, Isotype Control (HY-P99003).
    CT140
  • HY-RS03277

    Small Interfering RNA (siRNA) Others

    CT45A1 Human Pre-designed siRNA Set A contains three designed siRNAs for CT45A1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    CT45A1 Human Pre-designed siRNA Set A
    CT45A1 Human Pre-designed siRNA Set A
  • HY-P99750

    CT-P23

    Influenza Virus Infection
    Navivumab (CT-P23) is an influenza A virus hemagglutinin HA monoclonal antibody. neutralizes H1, H2, H5, and H9 influenza A viruses by binding to the stem fusion domain in HA2 .
    Navivumab
  • HY-P99346

    CT-P59

    SARS-CoV Angiotensin-converting Enzyme (ACE) Infection
    Regdanvimab (CT-P59) is a human monoclonal antibody that targets the receptor-binding domain of SARS-CoV-2 spike protein, blocking interaction with ACE2 for viral entry. Regdanvimab can be used for the research of COVID-19 .
    Regdanvimab
  • HY-111669
    Zervimesine
    1 Publications Verification

    CT1812; Sigma-2 receptor antagonist 1

    Sigma Receptor Neurological Disease
    Zervimesine (CT1812) is an orally active and brain penetrant sigma-2 receptor antagonist with a Ki of 8.5 nM. Zervimesine can be used for the research of Alzheimer’s disease .
    Zervimesine
  • HY-103712

    CT7001; ICEC0942

    CDK Apoptosis Cancer
    Samuraciclib (CT7001) is a potent, selective, ATP-competitive and orally active CDK7 inhibitor, with an IC50 of 41 nM. Samuraciclib displays 45-, 15-, 230- and 30-fold selectivity over CDK1, CDK2 (IC50 of 578 nM), CDK5 and CDK9, respectively. Samuraciclib inhibits the growth of breast cancer cell lines with GI50 values between 0.2-0.3 μM. Samuraciclib has anti-tumor effects .
    Samuraciclib
  • HY-103712A
    Samuraciclib hydrochloride
    5+ Cited Publications

    CT7001 hydrochloride; ICEC0942 hydrochloride

    CDK Apoptosis Cancer
    Samuraciclib hydrochloride (CT7001 hydrochloride) is a potent, selective, ATP-competitive and orally active CDK7 inhibitor, with an IC50 of 41 nM. Samuraciclib hydrochloride displays 45-, 15-, 230- and 30-fold selectivity over CDK1, CDK2 (IC50 of 578 nM), CDK5 and CDK9, respectively. Samuraciclib hydrochloride inhibits the growth of breast cancer cell lines with GI50 values between 0.2-0.3 µM. Samuraciclib hydrochloride has anti-tumor effects .
    Samuraciclib hydrochloride
  • HY-103712C

    CT7001 hydrochloride hydrate; ICEC0942 hydrochloride hydrate

    CDK Apoptosis Cancer
    Samuraciclib (CT7001) hydrochloride hydrate is a potent, selective, ATP-competitive and orally active CDK7 inhibitor, with an IC50 of 41 nM. Samuraciclib hydrochloride hydrate displays 45-, 15-, 230- and 30-fold selectivity over CDK1, CDK2 (IC50 of 578 nM), CDK5 and CDK9, respectively. Samuraciclib hydrochloride hydrate inhibits the growth of breast cancer cell lines with GI50 values between 0.2-0.3 μM. Samuraciclib hydrochloride hydrate has anti-tumor effects .
    Samuraciclib hydrochloride hydrate
  • HY-103712B

    CT7001 hydrochloride dihydrate; ICEC0942 hydrochloride dihydrate

    CDK Apoptosis Cancer
    Samuraciclib (CT7001) hydrochloride hydrate is a potent, selective, ATP-competitive and orally active CDK7 inhibitor, with an IC50 of 41 nM. Samuraciclib hydrochloride hydrate displays 45-, 15-, 230- and 30-fold selectivity over CDK1, CDK2 (IC50 of 578 nM), CDK5 and CDK9, respectively. Samuraciclib hydrochloride hydrate inhibits the growth of breast cancer cell lines with GI50 values between 0.2-0.3 μM. Samuraciclib hydrochloride hydrate has anti-tumor effects .
    Samuraciclib hydrochloride dihydrate
  • HY-10202
    Tandutinib
    5 Publications Verification

    MLN518; CT53518

    FLT3 c-Kit PDGFR Apoptosis Cancer
    Tandutinib (MLN518) is a potent and selective inhibitor of the FLT3 with an IC50 of 0.22 μM, and also inhibits c-Kit and PDGFR with IC50s of 0.17 μM and 0.20 μM, respectively. Tandutinib can be used for acute myelogenous leukemia (AML) . Tandutinib has the ability to cross the blood-brain barrier .
    Tandutinib
  • HY-P9970
    Infliximab
    10+ Cited Publications

    Avakine; CT-P13

    TNF Receptor Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Infliximab (Avakine) is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α. Infliximab prevents the interaction of TNF-α with TNF-α receptor (TNFR1 and TNFR2). Infliximab has the potential for autoimmune, chronic inflammatory diseases and diabetic neuropathy research .
    Infliximab
  • HY-10182B
    Laduviglusib trihydrochloride
    Maximum Cited Publications
    218 Publications Verification

    CHIR-99021 trihydrochloride; CT99021 trihydrochloride

    Organoid GSK-3 Wnt β-catenin Autophagy Cancer
    Laduviglusib (CHIR-99021) trihydrochloride is a potent and selective GSK-3α/β inhibitor with IC50s of 10 nM and 6.7 nM. Laduviglusib trihydrochloride shows >500-fold selectivity for GSK-3 over CDC2, ERK2 and other protein kinases. Laduviglusib trihydrochloride is also a potent Wnt/β-catenin signaling pathway activator. Laduviglusib trihydrochloride enhances mouse and human embryonic stem cells self-renewal. Laduviglusib trihydrochloride induces autophagy .
    Laduviglusib trihydrochloride
  • HY-10202A
    Tandutinib hydrochloride
    5 Publications Verification

    MLN518 hydrochloride; CT53518 hydrochloride

    FLT3 c-Kit PDGFR Apoptosis Cancer
    Tandutinib hydrochloride (MLN518 hydrochloride) is a potent and selective inhibitor of the FLT3 with an IC50 of 0.22 μM, and also inhibits c-Kit and PDGFR with IC50s of 0.17 μM and 0.20 μM, respectively. Tandutinib hydrochloride can be used for acute myelogenous leukemia (AML) . Tandutinib hydrochloride has the ability to cross the blood-brain barrier .
    Tandutinib hydrochloride
  • HY-10182
    Laduviglusib
    Maximum Cited Publications
    218 Publications Verification

    CHIR-99021; CT99021

    Organoid GSK-3 Wnt β-catenin Autophagy Metabolic Disease Cancer
    Laduviglusib (CHIR-99021) is a potent, selective and orally active GSK-3α/β inhibitor with IC50s of 10 nM and 6.7 nM. Laduviglusib shows >500-fold selectivity for GSK-3 over CDC2, ERK2 and other protein kinases. Laduviglusib is also a potent Wnt/β-catenin signaling pathway activator. Laduviglusib enhances mouse and human embryonic stem cells self-renewal. Laduviglusib induces autophagy .
    Laduviglusib
  • HY-10182A
    Laduviglusib monohydrochloride
    Maximum Cited Publications
    218 Publications Verification

    CHIR-99021 monohydrochloride; CT99021 monohydrochloride

    Organoid GSK-3 Wnt β-catenin Autophagy Cancer
    Laduviglusib (CHIR-99021) monohydrochloride is a potent and selective GSK-3α/β inhibitor with IC50s of 10 nM and 6.7 nM. Laduviglusib monohydrochloride shows >500-fold selectivity for GSK-3 over CDC2, ERK2 and other protein kinases. Laduviglusib monohydrochloride is also a potent Wnt/β-catenin signaling pathway activator. Laduviglusib monohydrochloride enhances mouse and human embryonic stem cells self-renewal. Laduviglusib monohydrochloride induces autophagy .
    Laduviglusib monohydrochloride
  • HY-10202AR

    MLN518 hydrochloride (Standard); CT53518 hydrochloride (Standard)

    Reference Standards FLT3 c-Kit PDGFR Apoptosis Cancer
    Tandutinib (hydrochloride) (Standard) is the analytical standard of Tandutinib (hydrochloride). This product is intended for research and analytical applications. Tandutinib hydrochloride (MLN518 hydrochloride) is a potent and selective inhibitor of the FLT3 with an IC50 of 0.22 μM, and also inhibits c-Kit and PDGFR with IC50s of 0.17 μM and 0.20 μM, respectively. Tandutinib hydrochloride can be used for acute myelogenous leukemia (AML) . Tandutinib hydrochloride has the ability to cross the blood-brain barrier .
    Tandutinib hydrochloride (Standard)
  • HY-10202R

    MLN518 (Standard); CT53518 (Standard)

    Reference Standards FLT3 c-Kit PDGFR Apoptosis Cancer
    Tandutinib (Standard) is the analytical standard of Tandutinib. This product is intended for research and analytical applications. Tandutinib (MLN518) is a potent and selective inhibitor of the FLT3 with an IC50 of 0.22 μM, and also inhibits c-Kit and PDGFR with IC50s of 0.17 μM and 0.20 μM, respectively. Tandutinib can be used for acute myelogenous leukemia (AML) . Tandutinib has the ability to cross the blood-brain barrier .
    Tandutinib (Standard)
  • HY-10182BR

    CHIR-99021 trihydrochloride (Standard); CT99021 trihydrochloride (Standard)

    Organoid Reference Standards GSK-3 Wnt β-catenin Autophagy Cancer
    Laduviglusib (trihydrochloride) (Standard) is the analytical standard of Laduviglusib (trihydrochloride). This product is intended for research and analytical applications. Laduviglusib (CHIR-99021) trihydrochloride is a potent and selective GSK-3α/β inhibitor with IC50s of 10 nM and 6.7 nM. Laduviglusib trihydrochloride shows >500-fold selectivity for GSK-3 over CDC2, ERK2 and other protein kinases. Laduviglusib trihydrochloride is also a potent Wnt/β-catenin signaling pathway activator. Laduviglusib trihydrochloride enhances mouse and human embryonic stem cells self-renewal. Laduviglusib trihydrochloride induces autophagy .
    Laduviglusib trihydrochloride (Standard)
  • HY-10182R

    CHIR-99021 (Standard); CT99021 (Standard)

    Organoid GSK-3 Autophagy Wnt β-catenin Reference Standards Cancer
    Laduviglusib (Standard) is the analytical standard of Laduviglusib. Laduviglusib (CHIR-99021) is a potent, selective and orally active GSK-3α/β inhibitor with IC50s of 10 nM and 6.7 nM. Laduviglusib shows >500-fold selectivity for GSK-3 over CDC2, ERK2 and other protein kinases. Laduviglusib is also a potent Wnt/β-catenin signaling pathway activator. Laduviglusib enhances mouse and human embryonic stem cells self-renewal. Laduviglusib induces autophagy .
    Laduviglusib (Standard)
  • HY-10182G
    Laduviglusib
    1 Publications Verification

    CHIR-99021; CT99021

    GSK-3 Wnt β-catenin Autophagy Metabolic Disease Cancer
    Laduviglusib (CHIR-99021) (GMP) is Laduviglusib (HY-10182) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Laduviglusib is a potent, orally active and selective GSK-3α/β inhibitor.
    Laduviglusib
  • HY-10182AR

    CHIR-99021 monohydrochloride (Standard); CT99021 monohydrochloride (Standard)

    Organoid Reference Standards GSK-3 Wnt β-catenin Autophagy Cancer
    Laduviglusib (monohydrochloride) (Standard) is the analytical standard of Laduviglusib (monohydrochloride). This product is intended for research and analytical applications. Laduviglusib (CHIR-99021) monohydrochloride is a potent and selective GSK-3α/β inhibitor with IC50s of 10 nM and 6.7 nM. Laduviglusib monohydrochloride shows >500-fold selectivity for GSK-3 over CDC2, ERK2 and other protein kinases. Laduviglusib monohydrochloride is also a potent Wnt/β-catenin signaling pathway activator. Laduviglusib monohydrochloride enhances mouse and human embryonic stem cells self-renewal. Laduviglusib monohydrochloride induces autophagy .
    Laduviglusib monohydrochloride (Standard)
  • HY-P9970A

    Avakine (Anti-TNF-α); CT-P13 (Anti-TNF-α)

    TNF Receptor Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Infliximab (Anti-TNF-α) (Avakine (Anti-TNF-α)) is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α. Infliximab (Anti-TNF-α) prevents the interaction of TNF-α with TNF-α receptor (TNFR1 and TNFR2). Infliximab (Anti-TNF-α) has the potential for autoimmune, chronic inflammatory diseases and diabetic neuropathy research .
    Infliximab (Anti-TNF-α)
  • HY-12354R

    MMP Cancer
    SB-3CT (Standard) is the analytical standard of SB-3CT. This product is intended for research and analytical applications. SB-3CT is a potent and competitive matrix metalloproteinase MMP-2 and MMP-9 inhibitor with Ki values of 13.9 and 600 nM, respectively. SB-3CT has high selectivity for gelatinases. SB-3CT shows blood-brain barrier permeability and has neuroprotective effects and anticancer activity .
    SB-3CT (Standard)
  • HY-12354
    SB-3CT
    20+ Cited Publications

    MMP Cancer
    SB-3CT is a potent and competitive matrix metalloproteinase MMP-2 and MMP-9 inhibitor with Ki values of 13.9 and 600 nM, respectively. SB-3CT has high selectivity for gelatinases. SB-3CT shows blood-brain barrier permeability and has neuroprotective effects and anticancer activity .
    SB-3CT
  • HY-P10652

    Wnt β-catenin Cancer
    hsBCL9CT-24 is a Wnt/β-catenin (b-cat) pathway inhibitor with potent anti-tumor effect. hsBCL9CT-24 reactivates anti-cancer immune response suppressed by the oncogenic Wnt pathway and can be utilized for cancer research .
    hsBCL9CT-24
  • HY-100942

    5-CT maleate

    5-HT Receptor Neurological Disease
    5-Carboxamidotryptamine maleate (5-CT maleate) is a potent 5-HT1A, 5-HT1B, 5-HT1D, 5-HT5 and 5-HT7 receptors agonist .
    5-Carboxamidotryptamine maleate
  • HY-P990842

    Transmembrane Glycoprotein Others
    Anti-GPC-2 Antibody (CT3) is a kind of mouse IgG1, κ chimeric antibody, targeting to human GPC-2. The recommend isotype control of Anti-GPC-2 Antibody (CT3): Mouse IgG1 kappa, Isotype Control (HY-P99977).
    Anti-GPC-2 Antibody (CT3)
  • HY-135555

    5-CT

    5-HT Receptor Neurological Disease
    5-Carboxamidotryptamine (5-CT) is a 5-HT1A, 5-HT1B, 5-HT1D, 5-HT5A, 5-HT7 receptor agonist . 5-Carboxamidotryptamine has a Ki value of 4.6 nM for cloned human 5-HT5A receptor. 5-Carboxamidotryptamine causes a dose-dependent reduction in rectal temperature of mice .
    5-Carboxamidotryptamine
  • HY-B1410

    MP-328

    Biochemical Assay Reagents Others Cancer
    Ioversol (MP-328) is a nonionic iodinated contrast medium (CM) that is used during a CT scan or x-ray in animal experiment. Ioversol does not damage the blood-brain barrier (BBB) in animal .
    Ioversol
  • HY-B1410R

    MP-328 (Standard)

    Biochemical Assay Reagents Reference Standards Others Cancer
    Ioversol (Standard) is the analytical standard of Ioversol. This product is intended for research and analytical applications. Ioversol (MP-328) is a nonionic iodinated contrast medium (CM) that is used during a CT scan or x-ray in animal experiment. Ioversol does not damage the blood-brain barrier (BBB) in animal [4].
    Ioversol (Standard)
  • HY-106586

    P-286

    Biochemical Assay Reagents Others
    Ioxaglic acid (P-286) is negatively charged contrast agent, is useful as an inverse indicator for glycosaminoglycan (GAG) used in computed tomography (CT). Ioxaglic acid can be used for imaging of human osteoarthritic cartilage via quantitative assessment of glycosaminoglycan content .
    Ioxaglic acid
  • HY-128890
    DOTA-​NHS-ester
    1 Publications Verification

    ADC Linker Cancer
    DOTA-NHS-ester is a linker for affibody molecules and is applied in small animals PET, SPECT, and CT. DOTA-NHS-ester can be used to label radiotherapeutic agents or imaging probes for the detection of tumors .
    DOTA-​NHS-ester
  • HY-P1136
    Gap19
    5 Publications Verification

    Gap Junction Protein Cardiovascular Disease
    Gap19, a peptide derived from nine amino acids of the Cx43 cytoplasmic loop (CL), is a potent and selective connexin 43 (Cx43) hemichannel blocker. Gap19 inhibits hemichannels caused by preventing intramolecular interactions of the C-terminus (CT) with the CL. Gap19 is not blocking GJ channels or Cx40/pannexin-1 hemichannels. Gap19 has protective effects against myocardial .
    Gap19
  • HY-P1136A
    Gap19 TFA
    5 Publications Verification

    Gap Junction Protein Cardiovascular Disease
    Gap19 TFA, a peptide derived from nine amino acids of the Cx43 cytoplasmic loop (CL), is a potent and selective connexin 43 (Cx43) hemichannel blocker. Gap19 TFA inhibits hemichannels caused by preventing intramolecular interactions of the C-terminus (CT) with the CL. Gap19 TFA is not blocking GJ channels or Cx40/pannexin-1 hemichannels. Gap19 TFA has protective effects against myocardial .
    Gap19 TFA

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: